A5064624695- Pharmaceutical Practices and Patient Outcomes
- Pharmaceutical studies and practices
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- Antimicrobial Resistance in Staphylococcus
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Pharmaceutical Economics and Policy
- Parvovirus B19 Infection Studies
- Lung Cancer Research Studies
- Gastroesophageal reflux and treatments
- Breast Cancer Treatment Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Medication Adherence and Compliance
- Chronic Myeloid Leukemia Treatments
- HIV/AIDS oral health manifestations
- CAR-T cell therapy research
- Immunodeficiency and Autoimmune Disorders
- Advancements in Semiconductor Devices and Circuit Design
- Esophageal Cancer Research and Treatment
- Inflammatory Biomarkers in Disease Prognosis
Hospital Universitario Virgen del Rocío
2009-2025
Andalusian Health Service
2016-2024
Universidad de Sevilla
2024
Hospital La Inmaculada
2016-2018
Memorial Hospital of South Bend
2002
Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene is gaining importance to be able predict fluoropyrimidine-associated toxicity. The aim of this project was describe frequency DPYD variants DPYD*2A (rs3918290); c.1679T>G (rs55886062); c.2846A>T (rs67376798) and c.1129-5923C>G (rs75017182; HapB3) Spanish oncological patients.Cross-sectional multicentric study (PhotoDPYD study) conducted hospitals located Spain designed register most relevant genetic patients. All...
ICIs have been able to improve overall survival in advanced-stage lung cancer. The benefit of this therapy is limited patients with poor ECOG PS. However, scale imprecise and can be influenced by different factors, such as frailty. Cancer a high risk frailty independently age. In observational, single-center, retrospective study, we investigated the effect on effectiveness pembrolizumab first-line use cohort 101 metastatic NSCLC. Frailty was determined using score system developed Sakakida...
The KEYNOTE-024 clinical trial showed promising results for pembrolizumab in the first-line of treatment advanced non-small-cell lung cancer (NSCLC). However, profile patients real-world practice differs from those included this trial. Here, an observational single-center retrospective study was performed through a comparative analysis outcomes after therapy according to Eastern Cooperative Oncology Group Stage Performance Status (ECOG PS). Moreover, univariate and multivariate analyses were...
Background Niraparib has been authorized for maintenance treatment of epithelial ovarian cancer after first-line with platinum, in partial or complete response. Objectives To evaluate the effectiveness and safety niraparib platinum-sensitive recurrent (PSROC) patients a tertiary hospital. Materials Methods This retrospective observational unicentre study included women diagnosed adenocarcinoma who received niraparib. Eligibility criteria encompassed PSROC, response to platinum chemotherapy,...
Introduction: Alectinib is a potent and selective orally active tyrosine kinase inhibitor used for anaplastic lymphoma kinase-positive non-small cell lung cancer, which has better safety profile than other inhibitors of kinase. We report case mixed pattern acute interstitial nephritis tubular necrosis proven by renal biopsy upon starting alectinib therapy. Case report: A 68-year-old man with diabetes, hypertension, dyslipidaemia, diagnosed cancer stage IV, had 27 days previously started 600...
Describir la estructura de Comisión Farmacia y Terapéutica el proceso selección nuevos medicamentos un hospital terciario. Se revisan todas las actas Guías para Incorporación Nuevos Fármacos recibidas en periodo 2004–2007 Hospital Universitario Virgen del Rocío. realiza estudio descriptivo que recoge variables relacionadas con fármaco (grupo terapéutico, vía registro, administración categoría legal), solicitante (servicio al pertenece, profesional tipo petición) resultado evaluación...
Abstract Background Pregabalin is a drug which requires dose adjustment when renal clearance decreases below 60 mL/min. Aim We describe case in 58‐year‐old woman, taking pregabalin for 3 years, developed symptoms of parkinsonism due to worsening her kidney failure. Clinical details A woman characterised by bradypsychia and drowsiness, inability ambulate, stiffness the extremities loss facial expression. Four days earlier patient had undergone an abdominal computed axial tomography scan with...
<h3>Background and Importance</h3> Sacituzumab-govitecan (SG) is a new antibody-drug conjugate approved for unresectable/metastatic triple negative breast cancer (TNBC), available from the end of 2022 in Spanish public health system, so there still little published real-life data. <h3>Aim Objectives</h3> To analyse effectiveness safety SG TNBC patients three main hospitals city. <h3>Material Methods</h3> Retrospective, observational, multicentre study was conducted, including all treated...
<h3>Background and Importance</h3> Heterogeneity in response to immunotherapy patients with advanced non-small-cell lung cancer (NSCLC) highlights the need identify predictive biomarkers. Peripheral blood biomarkers have been associated prognosis NSCLC treated immunotherapy. <h3>Aim Objectives</h3> To analyse correlation between pembrolizumab plus chemotherapy peripheral biomarker dynamics non-squamous metastatic NSCLC. <h3>Material Methods</h3> Retrospective observational study including...
Sacituzumab-govitecan (Sgov) is a new antibody-drug conjugate recently approved for metastatic triple negative breast cancer (mTNBC), so there are still few data published in the real-world setting.
Objetivo: analizar las características demográficas, clínicas y funcionales de personas residentes en un centro sociosanitario público. Caracterizar a la población función del riesgo anticolinérgico según escala DBI. Metodología: estudio observacional descriptivo una cohorte público Andalucía. Se llevó cabo desde septiembre hasta diciembre 2020.Se recogieron variables sociodemográficas, funcionales, farmacoterapia carga anticolinérgica asociada realizó análisis general otro diferencial...